Univariable analysis of transplants outcomes based on GVHD prophylaxis
| Outcome . | CNI based . | PTCy . | P value . |
|---|---|---|---|
| Myeloid engraftment, CI at 30 d (%) | 99 (96-100) | 95 (90-98) | <.001 |
| Platelet engraftment, CI at 60 d (%) | 97 (93-98) | 92 (86-95) | <.001 |
| aGVHD grades 2-4, CI at 100 d (%) | 31 (25-37) | 26 (19-33) | .31 |
| aGVHD grades 3-4, CI at 100 d (%) | 15 (11-20) | 10 (5-15) | .17 |
| Overall cGVHD, 2-y CI (%) | 43 (36-50) | 25 (18-33) | <.001 |
| Extensive cGVHD, 2-y CI (%) | 28 (22-34) | 13 (8-19) | .003 |
| NRM, 2-y CI (%) | 17 (12-22) | 11 (6-17) | .12 |
| Relapse, 2-y CI (%) | 30 (23-36) | 17 (11-24) | .007 |
| OS, 2-y CI (%) | 72 (66-77) | 85 (77-90) | .005 |
| PFS, 2-y CI (%) | 53 (46-60) | 72 (64-79) | <.001 |
| GRFS, 2-y CI (%) | 31 (25-38) | 59 (51-67) | <.001 |
| Outcome . | CNI based . | PTCy . | P value . |
|---|---|---|---|
| Myeloid engraftment, CI at 30 d (%) | 99 (96-100) | 95 (90-98) | <.001 |
| Platelet engraftment, CI at 60 d (%) | 97 (93-98) | 92 (86-95) | <.001 |
| aGVHD grades 2-4, CI at 100 d (%) | 31 (25-37) | 26 (19-33) | .31 |
| aGVHD grades 3-4, CI at 100 d (%) | 15 (11-20) | 10 (5-15) | .17 |
| Overall cGVHD, 2-y CI (%) | 43 (36-50) | 25 (18-33) | <.001 |
| Extensive cGVHD, 2-y CI (%) | 28 (22-34) | 13 (8-19) | .003 |
| NRM, 2-y CI (%) | 17 (12-22) | 11 (6-17) | .12 |
| Relapse, 2-y CI (%) | 30 (23-36) | 17 (11-24) | .007 |
| OS, 2-y CI (%) | 72 (66-77) | 85 (77-90) | .005 |
| PFS, 2-y CI (%) | 53 (46-60) | 72 (64-79) | <.001 |
| GRFS, 2-y CI (%) | 31 (25-38) | 59 (51-67) | <.001 |
aGVHD, acute graft-versus-host disease; CI, cumulative incidence.